Cargando…
Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals
Cardiovascular (CV) diseases are a serious concern in rheumatoid arthritis (RA), accounting for approximately one-third to one-half of all RA-related deaths. Besides the attempts to identify new risk factors, the proper management of traditional CV risk factors such as dyslipidemia should become a p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443999/ https://www.ncbi.nlm.nih.gov/pubmed/22991486 http://dx.doi.org/10.1155/2012/785946 |
_version_ | 1782243616652001280 |
---|---|
author | Popa, Calin D. Arts, Elke Fransen, Jaap van Riel, Piet L. C. M. |
author_facet | Popa, Calin D. Arts, Elke Fransen, Jaap van Riel, Piet L. C. M. |
author_sort | Popa, Calin D. |
collection | PubMed |
description | Cardiovascular (CV) diseases are a serious concern in rheumatoid arthritis (RA), accounting for approximately one-third to one-half of all RA-related deaths. Besides the attempts to identify new risk factors, the proper management of traditional CV risk factors such as dyslipidemia should become a priority in the periodic evaluation of every RA patient. Atherogenic index has been suggested to be less susceptible to disease activity variation during large periods of time, making him more attractive to be used in CV risk prediction in this group of patients as compared to individual lipids concentrations. Nevertheless, inflammation may negatively impact HDL antiatherogenic properties, suggesting that HDL function assessment is of particular importance when predicting CV risk in these patients. A tight control of inflammation becomes therefore crucial for a successful CV risk management. The present paper debates these hypotheses focusing on the effects of therapy with biologicals on the above mentioned parameters. |
format | Online Article Text |
id | pubmed-3443999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-34439992012-09-18 Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals Popa, Calin D. Arts, Elke Fransen, Jaap van Riel, Piet L. C. M. Mediators Inflamm Review Article Cardiovascular (CV) diseases are a serious concern in rheumatoid arthritis (RA), accounting for approximately one-third to one-half of all RA-related deaths. Besides the attempts to identify new risk factors, the proper management of traditional CV risk factors such as dyslipidemia should become a priority in the periodic evaluation of every RA patient. Atherogenic index has been suggested to be less susceptible to disease activity variation during large periods of time, making him more attractive to be used in CV risk prediction in this group of patients as compared to individual lipids concentrations. Nevertheless, inflammation may negatively impact HDL antiatherogenic properties, suggesting that HDL function assessment is of particular importance when predicting CV risk in these patients. A tight control of inflammation becomes therefore crucial for a successful CV risk management. The present paper debates these hypotheses focusing on the effects of therapy with biologicals on the above mentioned parameters. Hindawi Publishing Corporation 2012 2012-09-06 /pmc/articles/PMC3443999/ /pubmed/22991486 http://dx.doi.org/10.1155/2012/785946 Text en Copyright © 2012 Calin D. Popa et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Popa, Calin D. Arts, Elke Fransen, Jaap van Riel, Piet L. C. M. Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals |
title | Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals |
title_full | Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals |
title_fullStr | Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals |
title_full_unstemmed | Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals |
title_short | Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals |
title_sort | atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443999/ https://www.ncbi.nlm.nih.gov/pubmed/22991486 http://dx.doi.org/10.1155/2012/785946 |
work_keys_str_mv | AT popacalind atherogenicindexandhighdensitylipoproteincholesterolascardiovascularriskdeterminantsinrheumatoidarthritistheimpactoftherapywithbiologicals AT artselke atherogenicindexandhighdensitylipoproteincholesterolascardiovascularriskdeterminantsinrheumatoidarthritistheimpactoftherapywithbiologicals AT fransenjaap atherogenicindexandhighdensitylipoproteincholesterolascardiovascularriskdeterminantsinrheumatoidarthritistheimpactoftherapywithbiologicals AT vanrielpietlcm atherogenicindexandhighdensitylipoproteincholesterolascardiovascularriskdeterminantsinrheumatoidarthritistheimpactoftherapywithbiologicals |